Quarterly Activities Report and Appendix 4C
Filed with ASX · · 7 pages · English
• Filed new patent application in July covering DEP® technology in radioligand therapy (RLT), strengthening Starpharma’s intellectual property position in radiopharmaceuticals2. • Achieved a key milestone under the Radiopharm Theranostics collaboration, triggering a $0.5 million option fee and commencing the option period for an exclusive license3. • High engagement at the BIO International Conven
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP milestone triggers partner option fee
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP radiopharmaceutical data supports patent application
- FDA confirms path to DEP HER2 first-in-human study
- Half Yearly Report and Accounts
Later from Starpharma
- Fully Underwritten Entitlement Offer to Raise $32 Million
- Entitlement Offer Investor Presentation
- Successful Completion of $32 million Entitlement Offer
- Preliminary Final Report
- FY26 Key Financial Results and Annual Report
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma